Weight-loss jabs and those for diabetes linked to lower dementia risk
Weight-loss jabs and those for diabetes may be linked to a lower risk of dementia, a study suggests.
Semaglutide in particular, whose brand names include Wegovy and Ozempic, showed promise in cutting the risk of conditions that impair memory and thought processes, according to researchers.
Experts called for further research to shed light on how these drugs affect the brain and why they 'may be offering a protective effect'.
Academics in the US analysed data from type 2 diabetes patients who were either taking GLP-1 receptor agonists (GLP-1RAs), which work by reducing food cravings, or sodium-glucose cotransporter-2 inhibitors (SGLT-2i) which work by reducing the amount of glucose the kidneys re-absorb allowing it to pass out of the body in urine.
GLP-1RAs is a class of medication that includes semaglutide, whose brand names include the jabs Wegovy and Ozempic, as well as Rybelus, which is taken as a tablet.
Wegovy was approved to tackle weight loss on the NHS in 2023, while Ozempic and Rybelus are available on the health service as treatments for type 2 diabetes.
The study included the health records of 396,963 people from the OneFlorida+ Clinical Research Consortium from January 2014 to June 2023.
All were aged over 50 with type 2 diabetes and no diagnosis of Alzheimer disease and related dementias (ADRD).
Researchers compared those on GLP-1RAs, SGLT-2i and other, second-line glucose-lowering drugs.
The analysis found that 'both GLP-1RAs and SGLT2is were statistically significantly associated with decreased risk of ADRD compared with other GLDs, and no difference was observed between both drugs'.
Meanwhile, it was found that among the GLP-1RAs, 'semaglutide seems to be promising in reducing the risk of ADRD'.
'This finding is particularly intriguing given the existing research on semaglutide's neuroprotective properties,' researchers added.
Responding to the study, Dr Leah Mursaleen, head of clinical research at Alzheimer's Research UK, said: 'The results from this study support the growing evidence that GLP-1RA and SGLT-2 inhibitors medicines may reduce dementia risk.
'We don't know yet why these medicines may be offering a protective effect, and will need more research to understand how they are affecting the brain.'
She added that while the findings are 'interesting', it is important to consider if other factors might be influencing results like overall health, income or education.
It comes as researchers in Ireland suggested GLP-1RAs are 'associated with a statistically significant reduction in dementia'.
The study analysed 26 clinical trials involving almost 165,000 patients to determine if drugs like SGLT2is and GLP-1RAs, as well as diabetes medications metformin and pioglitazone, led to a reduction in risk of dementia or cognitive impairment.
It found most drugs 'were not associated with an overall reduction in all-cause dementia' although 'GLP-1RAs was associated with a statistically significant reduction in all-cause dementia'.
Both studies have been published in the journal Jama Neurology.
Dr Richard Oakley, director of research and innovation at Alzheimer's Society, said: 'Whilst both of these studies found a link between GLP-1RAs and reduced dementia risk, only one found SGLT2is, another class of diabetes drug, were also associated with a reduced risk.
'More research is needed to properly understand how diabetes treatments may lower the risk of dementia, by tracking people for longer, especially as they get older.'
Prof Tara Spires-Jones, director of the Centre for Discovery Brain Sciences at the University of Edinburgh, group leader in the UK Dementia Research Institute, and president of the British Neuroscience Association, said the data is 'encouraging' for the 'potential of using GLP-1Ras to lower dementia risk in people with diabetes'
'But even within these two strong studies, there are slightly conflicting results over SGLT2is highlighting the need for further research,' she added.
'It is important to note that these drugs do have side effects and that they are not guaranteed to prevent dementia.
'The studies had important limitations including a relatively short follow up time. Future work will be important to understand how risk factors like diabetes and obesity increase risk of dementia to develop effective treatments and prevention strategies.'
Masud Husain, a professor of neurology and cognitive neuroscience at the University of Oxford, added: 'For me, these new retrospective analyses suggest that GLP-1 receptor agonists, particularly semaglutide, might reduce the risk of developing dementia in people with type 2 diabetes.
'But we need data from prospective trials to provide stronger evidence.
'The wider question of whether such drugs might also be protective against dementia in people who don't have diabetes is a really intriguing one, and the focus of several ongoing clinical trials.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
South Wales Argus
an hour ago
- South Wales Argus
NHS spends £1.8bn a year on private firms, says GMB in call to end outsourcing
The GMB said requests using freedom of information laws to more than 200 trusts show they spend £1,831,105,580 annually on outsourced contracts. Almost half the trusts did not respond so the true figure could be far higher, it is claimed. A separate investigation found ambulance trusts across England spent £290 million on private ambulances during the past three years. The total annual spend has almost doubled since 2021/22, according to the data. The GMB said it wants to send a message to the Government from its annual congress in Brighton on Monday. Ambulance worker Mo Akbar will tell delegates: 'GMB members demand an end to privatisation. 'We must bring all outsourced services like cleaning, catering, and facilities back in-house. 'We demand real-terms restorative pay from the 14 years of brutal austerity. 'Workers and communities should have more say in how the NHS is run, ensuring decisions focus on patient care, not financial targets. Health outcomes are tied to poverty, housing, and working conditions, so NHS rebuilding must also address these inequalities. 'This Labour Government will have a crisis of legitimacy if they choose a path of further privatisation of the NHS, which would put at risk the sense of the collectivism that is at the heart of our health service 'We must be resolute in fighting for our National Health Service.'
North Wales Chronicle
2 hours ago
- North Wales Chronicle
Nurses to vote on pay deal amid concerns of industrial action
Around 345,000 members of the Royal College of Nursing (RCN) will be asked if the pay award is enough in what was described as the biggest single vote of the profession ever launched in the UK. Last month, the Westminster government accepted the recommendation of the Pay Review Body, giving nursing staff In England's NHS a pay rise of 3.6%. The RCN described the award as 'grotesque', saying it will see nursing staff receive a pay rise 'entirely swallowed up by inflation' – with doctors, teachers, prison officers and the armed forces all receiving a bigger increase. An identical award was made in Wales, while in Northern Ireland, the Health Minister has announced his wish to implement a 3.6% pay rise, but this is still to be agreed. The RCN said the vote will be crucial in determining the next steps, which could include a ballot for strike action. The vote will include RCN members working in the NHS in England, Wales and Northern Ireland. Speaking from an international nursing conference in Helsinki and on the launch of the vote, Professor Nicola Ranger, RCN general secretary, will say: 'I'm with nurses from around the world today asking why it is our ministers in the UK who have once again put nursing at the back of the queue when it comes to pay. 'Nursing is an incredible career, but despite being the most valued profession by the public we continue to be weighted to the bottom of the NHS pay scale and are set to receive one of the lowest pay awards. 'It is time to show that nurses are valued and, from today, hundreds of thousands of nursing staff working in the NHS will give their verdict on whether 3.6% is enough.' The RCN said nursing staff in England have faced more than a decade of pay erosion since 2010/11, with pay down by a quarter in real terms. As a result, there are more than 26,000 unfilled nursing posts, while student recruitment has 'collapsed' and the numbers quitting is 'skyrocketing', said the RCN. Professor Ranger will add: 'Over a decade of pay erosion has had a devastating impact on our profession, forcing increasing numbers into quitting while putting off the nurses of the future. 'When our members vote, they won't just be voting on the fairness of the award for themselves, but if it's enough to turn our profession around.' NHS workers including nurses staged a series of strikes under the previous Conservative government in bitter disputes over pay.
Rhyl Journal
2 hours ago
- Rhyl Journal
Nurses to vote on pay deal amid concerns of industrial action
Around 345,000 members of the Royal College of Nursing (RCN) will be asked if the pay award is enough in what was described as the biggest single vote of the profession ever launched in the UK. Last month, the Westminster government accepted the recommendation of the Pay Review Body, giving nursing staff In England's NHS a pay rise of 3.6%. The RCN described the award as 'grotesque', saying it will see nursing staff receive a pay rise 'entirely swallowed up by inflation' – with doctors, teachers, prison officers and the armed forces all receiving a bigger increase. An identical award was made in Wales, while in Northern Ireland, the Health Minister has announced his wish to implement a 3.6% pay rise, but this is still to be agreed. The RCN said the vote will be crucial in determining the next steps, which could include a ballot for strike action. The vote will include RCN members working in the NHS in England, Wales and Northern Ireland. Speaking from an international nursing conference in Helsinki and on the launch of the vote, Professor Nicola Ranger, RCN general secretary, will say: 'I'm with nurses from around the world today asking why it is our ministers in the UK who have once again put nursing at the back of the queue when it comes to pay. 'Nursing is an incredible career, but despite being the most valued profession by the public we continue to be weighted to the bottom of the NHS pay scale and are set to receive one of the lowest pay awards. 'It is time to show that nurses are valued and, from today, hundreds of thousands of nursing staff working in the NHS will give their verdict on whether 3.6% is enough.' The RCN said nursing staff in England have faced more than a decade of pay erosion since 2010/11, with pay down by a quarter in real terms. As a result, there are more than 26,000 unfilled nursing posts, while student recruitment has 'collapsed' and the numbers quitting is 'skyrocketing', said the RCN. Professor Ranger will add: 'Over a decade of pay erosion has had a devastating impact on our profession, forcing increasing numbers into quitting while putting off the nurses of the future. 'When our members vote, they won't just be voting on the fairness of the award for themselves, but if it's enough to turn our profession around.' NHS workers including nurses staged a series of strikes under the previous Conservative government in bitter disputes over pay.
